
X
Merck KGaA takes second option from cancer immunotherapy pact with F-Star
https://pharmaphorum.com/news/merck-kgaa-takes-second-option-from-cancer-immunotherapy-pact-with-f-star/
German Merck has option to licence LAG3-PDL1 drug.
Deal focuses on CNS bispecific antibodies.
Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.